TIGLUTIK
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- TIGLUTIK
- Generic name
- RILUZOLE
- Manufacturer
- Italfarmaco SPA
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 20b7165a-eb4d-42a0-b2d8-16eff90a214e
- SPL ID
- 2ba33fab-05a6-42db-9b4a-277bb3a30f29
- Version
- 1
- Effective date
- 2026-07-29
- Source export date
- 2026-09-28
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/4bbc9760f647649b787710953d978bd6419e899ba8b90f32c3d972aae43947f8/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:07:46
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 209080 | derived:openfda.application_number |
| application number | NDA209080 | openfda.application_number | |
| brand name | TIGLUTIK | openfda.brand_name | |
| generic name | RILUZOLE | openfda.generic_name | |
| manufacturer name | Italfarmaco SPA | openfda.manufacturer_name | |
| ndc | package | 11797-210-01 | openfda.package_ndc |
| ndc | product | 11797-210 | openfda.product_ndc |
| ndc11 | package | 11797021001 | derived:openfda.package_ndc |
| rxcui | 2059266 | openfda.rxcui | |
| rxcui | 2058147 | openfda.rxcui | |
| spl id | 2ba33fab-05a6-42db-9b4a-277bb3a30f29 | id | |
| spl set id | 20b7165a-eb4d-42a0-b2d8-16eff90a214e | set_id | |
| unii | 7LJ087RS6F | openfda.unii |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.